← Back to Blood Work Guide

Blood Work Education

CARDIOVASCULAR & LIPIDS

Understanding your heart health markers — what Total Cholesterol, LDL, HDL, Triglycerides, ApoB, and Lp(a) mean for your cardiovascular risk.

Medically reviewed by Missy Zammichieli, DNP, APRN, FNP-BC ยท Updated March 2, 2026

Cardiovascular and lipid blood panel results

THE BOTTOM LINE

  • • Your lipid panel measures the fats in your blood that drive heart disease risk.
  • • LDL and ApoB are the markers that matter most for plaque buildup in your arteries.
  • • “Good” vs “bad” cholesterol is an oversimplification — this article explains what actually matters.
  • • Triglycerides connect your heart health to your metabolic health, especially insulin resistance.

INTRODUCTION

Heart disease is the leading cause of death in the United States. Roughly one in five deaths is linked to it. A lipid panel is one of the most common and useful blood tests for understanding your risk.

For years, the conversation was simple: “bad cholesterol” versus “good cholesterol.” That framing is incomplete. We now know that the number of cholesterol-carrying particles in your blood (measured by ApoB), genetic risk factors like Lp(a), and metabolic markers like triglycerides all matter significantly.

This article explains each marker in your panel — what it measures, why you should care, and what the target ranges are. If you are looking for strategies for improving your cardiovascular markers, we cover optimization approaches in a separate guide. Nothing here is medical advice. It is educational information based on published research and clinical guidelines.

YOUR BIOMARKERS EXPLAINED

1. Total Cholesterol

Why you should care: Total cholesterol is the sum of all cholesterol in your blood. It is the starting point, but it is a blunt tool. Someone with high HDL (“good” cholesterol) could have an elevated total number while actually being at lower risk. It is most useful as part of ratios and calculations — not on its own.

Target range: Below 200 mg/dL is considered desirable. 200-239 is borderline high. 240+ is high.

What pushes it up or down:

  • Higher: Diets high in saturated/trans fats, genetics, hypothyroidism, liver disease
  • Lower: Statin therapy, hyperthyroidism, malnutrition

2. LDL Cholesterol (Low-Density Lipoprotein)

Why you should care: LDL is the single most important number for predicting plaque buildup in your arteries. It is the type of cholesterol that penetrates artery walls and drives heart disease. Large-scale research has consistently shown that lowering LDL reduces cardiovascular events. Every 39 mg/dL reduction is associated with roughly a 22% drop in major heart events.

Target range: Most guidelines target LDL below 100 mg/dL for the general population and below 70 mg/dL for people with existing heart disease or high risk. Some European guidelines push even lower — below 55 mg/dL for very high-risk patients.

What pushes it up or down:

  • Higher: Saturated/trans fat intake, genetics (familial high cholesterol affects ~1 in 250 people), obesity, diabetes, hypothyroidism
  • Lower: Statins, ezetimibe, PCSK9 inhibitors, weight loss, dietary changes

3. HDL Cholesterol (High-Density Lipoprotein)

Why you should care: HDL is the “cleanup crew.” It picks up cholesterol from your artery walls and carries it back to the liver for disposal. Higher levels have been consistently linked to lower heart disease risk. But here is the catch: drugs that artificially raise HDL have failed to reduce heart attacks in clinical trials. That means HDL is a useful indicator of health, but forcing it higher with medication does not help. How well your HDL particles function may matter more than the raw number.

Target range: Below 40 mg/dL in men or below 50 mg/dL in women is considered a risk factor. There is no specific upper target — higher is generally better.

What pushes it up or down:

  • Higher: Regular exercise, moderate alcohol, weight loss
  • Lower: Smoking, inactivity, obesity, type 2 diabetes, very-high-carb diets

4. Triglycerides

Why you should care: Triglycerides are the most common fat in your blood. Your body converts excess calories — especially from carbs and alcohol — into triglycerides. Elevated triglycerides are one of the strongest blood markers of insulin resistance and metabolic problems. Very high levels (above 500 mg/dL) also carry risk for pancreatitis.

Target range: Below 150 mg/dL is normal. 150-199 is borderline high. 200-499 is high. 500+ is very high and needs attention.

What pushes it up or down:

  • Higher: Excess calories (especially refined carbs and sugar), alcohol, inactivity, obesity, poorly controlled diabetes, certain medications
  • Lower: Weight loss, reduced carb intake, exercise, omega-3 fatty acids, fibrate medications
  • Note: Whether you fasted matters — non-fasting samples run higher

5. Non-HDL Cholesterol

Why you should care: Non-HDL is simply total cholesterol minus HDL. It captures all the cholesterol in particles that can build up in your arteries — not just LDL, but also VLDL and other leftover fat particles. Research shows it is actually a stronger predictor of heart events than LDL alone. It is especially useful if your triglycerides are elevated, because in that case LDL alone can underestimate your real risk.

Target range: Generally 30 mg/dL above whatever LDL target applies to you. For most people, below 130 mg/dL. For high-risk patients, below 100 mg/dL.

What pushes it up or down:

  • Same factors as LDL and triglycerides. Elevated triglycerides in particular can drive non-HDL high even when LDL looks normal.

6. Apolipoprotein B (ApoB)

Why you should care: ApoB is arguably the most important number on an advanced lipid panel. Every cholesterol particle that can build plaque in your arteries carries exactly one ApoB molecule. So measuring ApoB gives you a direct count of how many dangerous particles are circulating in your blood.

Here is why that matters: two people can have the same LDL number but very different numbers of particles. If you have many small, cholesterol-depleted particles, your LDL looks “normal” but your actual particle count (ApoB) is high — and your risk tracks with the particle count. Growing expert consensus now considers ApoB superior to LDL for assessing risk.

Target range: Below 90 mg/dL for moderate risk. Below 80 mg/dL for high risk. Below 65 mg/dL for very high risk.

What pushes it up or down:

  • Higher: Saturated fat, genetics, insulin resistance, obesity, diabetes — notably, insulin resistance can raise ApoB even when LDL stays normal
  • Lower: Statins, PCSK9 inhibitors, ezetimibe, weight loss, dietary changes

7. Lipoprotein(a) [Lp(a)]

Why you should care: Lp(a) is a genetic wildcard. Your level is almost entirely determined by your DNA and stays stable your whole life. About 20% of the population has elevated Lp(a), making it a hidden risk factor that would never show up on a standard lipid panel. Elevated Lp(a) independently increases risk for heart disease and aortic valve problems.

The hard part: diet, exercise, and most cholesterol medications (including statins) do not lower it. PCSK9 inhibitors reduce it modestly (20-30%), and dedicated Lp(a)-lowering drugs are in late-stage clinical trials. Current guidelines recommend measuring Lp(a) at least once in your lifetime.

Target range: Below 50 mg/dL (or ~125 nmol/L). Levels above this are considered a risk-enhancing factor.

What pushes it up or down:

  • Primarily genetic — lifestyle changes have minimal effect
  • PCSK9 inhibitors provide moderate reduction
  • Kidney disease and hypothyroidism can modestly affect levels

8. Total Cholesterol / HDL Ratio

Why you should care: This ratio captures information that neither number shows alone. A total cholesterol of 220 with an HDL of 70 (ratio: 3.1) looks very different from a total cholesterol of 220 with an HDL of 35 (ratio: 6.3). The Framingham Heart Study found this ratio was a stronger predictor of heart disease than either number by itself. While ApoB has largely superseded it, the ratio remains a quick and useful screening metric.

Target range: Below 5.0 is desirable. Below 3.5 is associated with lower risk. Most useful as a trend over time.

What changes it:

  • Anything that raises total cholesterol or lowers HDL worsens (increases) the ratio
  • Exercise, weight loss, and dietary changes that lower LDL all improve it

HOW THESE MARKERS TELL A STORY TOGETHER

No single marker tells the full story. The real value is in how they relate to one another.

LDL alone is not enough. LDL and ApoB can disagree — your LDL looks fine, but your ApoB is high. This is common in people with metabolic syndrome, type 2 diabetes, or elevated triglycerides. When they disagree, risk tracks with ApoB, not LDL. This is exactly why ApoB is on your panel.

The triglyceride/HDL combo is a metabolic alarm. High triglycerides plus low HDL is one of the most reliable blood markers of insulin resistance. When you see this pattern, the liver is overproducing fat-carrying particles in response to metabolic dysfunction. A triglyceride-to-HDL ratio above 3.5 is a signal worth paying attention to.

When your numbers agree vs when they don’t. When LDL, non-HDL, and ApoB all point the same direction, interpretation is simple. The important cases are when they disagree. If your LDL is 110 but your ApoB is 120, you have more dangerous particles than LDL alone would suggest. Non-HDL often catches this gap, which is why guidelines recommend tracking it alongside LDL.

Lp(a) is a one-time genetic check. Because it is set by your DNA and stable over time, you do not need to recheck it. One measurement tells you if this hidden risk factor is present. If it is elevated, it shifts your entire risk picture upward.

Metabolic dysfunction reshapes everything. Insulin resistance does not just raise blood sugar. It raises triglycerides, lowers HDL, increases the number of small dense LDL particles, raises ApoB, and increases leftover fat particles. This is why a “normal” LDL in someone with metabolic syndrome can be misleading. The particle count and total atherogenic burden may be much higher than LDL suggests.

WHAT AFFECTS THESE RESULTS

Diet

Saturated fat raises LDL in most people. Trans fats raise LDL and lower HDL — a double hit. Soluble fiber (oats, psyllium, legumes) can lower LDL by 5-10%. Omega-3s at high doses lower triglycerides by 20-30%. Dietary cholesterol has a smaller effect than once believed — saturated and trans fats matter more.

Exercise

Aerobic exercise raises HDL and lowers triglycerides. It also improves insulin sensitivity, which has positive ripple effects across your entire lipid panel. More volume and intensity generally means bigger improvements.

Sleep

Short or poor sleep is linked to higher triglycerides, lower HDL, and increased insulin resistance.

Alcohol

Moderate drinking raises HDL but also raises triglycerides. Current evidence does not support starting to drink for heart health.

Medications

Statins lower LDL by 30-50%. Ezetimibe adds another 15-20%. PCSK9 inhibitors can cut LDL by 50-60% and modestly lower Lp(a). These are clinical decisions between you and your provider.

Weight Loss

Even modest weight loss (5-10% of body weight) improves virtually every lipid marker — lowering LDL, triglycerides, and ApoB while raising HDL.

Supplements

Plant sterols (2g/day) lower LDL by about 6-10%. Red yeast rice contains natural statin-like compounds. Berberine has shown LDL-lowering effects in studies. Discuss any supplements with your provider.

COMMON QUESTIONS

“Should I fast before my lipid panel?”

Not necessarily. Expert consensus now supports non-fasting testing for routine screening. Non-fasting samples work just as well for risk prediction. Fasting may still be preferred if your triglycerides are known to be elevated or if a previous non-fasting result came back above 400 mg/dL.

“My total cholesterol is high but my ratios look good — should I worry?”

Total cholesterol alone is a poor predictor of risk. If your total is high mainly because your HDL is high, and your LDL, non-HDL, and ApoB are all in range, the overall picture may be less concerning than the total number suggests. Flip side: a “normal” total cholesterol with low HDL and high triglycerides can actually be a higher-risk pattern. This is exactly why a comprehensive panel matters.

“Is cholesterol from food the problem?”

Less than you might think. For most people, dietary cholesterol has a modest effect because the body compensates by adjusting its own production. The US Dietary Guidelines removed the previous daily cholesterol limit for this reason. Saturated and trans fats have a much bigger impact on your LDL than dietary cholesterol does. That said, individual responses vary — some people are more sensitive to dietary cholesterol due to genetics.

“How often should lipids be rechecked?”

According to AHA guidelines, every 4-6 years for average-risk adults starting at age 20. More frequently (every 3-12 months) if you are actively managing your levels with lifestyle changes or medications. Lp(a) only needs to be measured once since it is genetically determined and stable.

References

  • 1. World Health Organization. Cardiovascular diseases (CVDs) fact sheet. WHO. 2021. Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
  • 2. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics — 2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-e621.
  • 3. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4(12):1287-1295.
  • 4. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472.
  • 5. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease — six-year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33-50.
  • 6. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143.
  • 7. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
  • 8. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
  • 9. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.
  • 10. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 — full report. J Clin Lipidol. 2015;9(2):129-169.
  • 11. Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet. 2014;384(9943):618-625.
  • 12. AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267.
  • 13. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089-2099.
  • 14. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127-135.
  • 15. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321.
  • 16. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292-2333.
  • 17. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302-1309.
  • 18. Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014;129(5):553-561.
  • 19. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-2853.
  • 20. O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483-1492.
  • 21. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244-255.
  • 22. McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol. 2005;96(3):399-404.
  • 23. US Department of Health and Human Services, US Department of Agriculture. 2015-2020 Dietary Guidelines for Americans. 8th ed. December 2015. Available at: https://health.gov/dietaryguidelines/2015/.
  • 24. Anderson JW, Allgood LD, Lawrence A, et al. Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. Am J Clin Nutr. 2000;71(2):472-479.
  • 25. Kodama S, Tanaka S, Saito K, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med. 2007;167(10):999-1008.
  • 26. Knutson KL. Sleep duration and cardiometabolic risk: a review of the epidemiologic evidence. Best Pract Res Clin Endocrinol Metab. 2010;24(5):731-743.
  • 27. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points — a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37(25):1944-1958.

UNDERSTAND YOUR NUMBERS

60+ biomarkers. In-person review. No referral needed.

Book Blood Panel